HIV infection and high density lipoprotein metabolism

Atherosclerosis

Volumn 199, Issue 1, 2008, Pages 79-86

  Rose, Honor ^a   Hoy, Jennifer ^b,c   Woolley, Ian ^b,c   Tchoua, Urbain ^a   Bukrinsky, Michael ^d   Dart, Anthony ^a   Sviridov, Dmitri ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Atherosclerosis; Dyslipidemia; High density lipoprotein; HIV

Indexed keywords

AMPRENAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATAZANAVIR; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; TRIGLYCERIDES;

EID: 45249102216     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.10.018     Document Type: Article

References (32)

1. Escaut L., Monsuez J.J., Chironi G., et al. Coronary artery disease in HIV infected patients. Intensive Care Med 29 (2003) 969-973
2. Varriale P., Saravi G., Hernandez E., and Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 147 (2004) 55-59
3. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
4. Hsue P.Y., Lo J.C., Franklin A., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109 (2004) 1603-1608
5. de Saint Martin L., Vandhuick O., Guillo P., et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 185 (2006) 361-367
6. Crook M.A., and Mir N. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it?. Int J STD AIDS 10 (1999) 353-356
7. Shor-Posner G., Basit A., Lu Y., et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 94 (1993) 515-519
8. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
9. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
10. Carpentier A., Patterson B.W., Uffelman K.D., et al. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 178 (2005) 165-172
11. El-Sadr W., Mullin C., Carr A., et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 6 (2005) 114-121
12. Shafran S., Mashinter L., and Roberts S. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 6 (2005) 421-425
13. van Leth F., Phanuphak P., Stroes E., et al. Nevirapine and Efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naive patients infected with HIV-1. PLoS Med 1 (2004) 64-74
14. Rose H., Woolley I., Hoy J., et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism 55 (2006) 90-95
15. Mujawar Z., Rose H., Morrow M.P., et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4 (2006) e365
16. Olchawa B., Kingwell B.A., Hoang A., et al. Physical fitness and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 24 (2004) 1087-1091
17. Miyazaki O., Kobayashi J., Fukamachi I., et al. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J Lipid Res 41 (2000) 2083-2088
18. Bielicki J.K., Forte T.M., McCall M.R., et al. High density lipoprotein particle size restriction in apolipoprotein A-I (Milano) transgenic mice. J Lipid Res 38 (1997) 2314-2321
19. Jauhiainen M., Metso J., Pahlman R., et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268 (1993) 4032-4036
20. Miida T., Obayashi K., Seino U., et al. LCAT-dependent conversion rate is a determinant of plasma prebeta1-HDL concentration in healthy Japanese. Clin Chim Acta 350 (2004) 107-114
21. Rimland D., Guest J., Hernandez I., et al. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Med 6 (2005) 326-333
22. Inazu A., Quinet E.M., Wang S., et al. Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry 31 (1992) 2352-2358
23. Greene D.J., Skeggs J.W., and Morton R.E. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 276 (2001) 4804-4811
24. Moore R.E., Kawashiri S M.-A., Kitajima K., et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 23 (2003) 1914-1920
25. Boekholdt S.M., Kuivenhoven J.-A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation 110 (2004) 1418-1423
26. Foger B., Ritsch A., Doblinger A., et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 16 (1996) 1430-1436
27. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (2003) 2978-2982
28. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 1857-1862
29. Oram J.F., Wolfbauer G., Vaughan A.M., et al. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem 278 (2003) 52379-52385
30. Dube M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37 (2003) 613-627
31. Tashima K.T., Bausserman L., Alt E.N., et al. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 4 (2003) 29-36
32. Tall A.R., Yvan-Charvet L., and Wang N. The failure of Torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260